Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation

Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009;23:1904–12.

Article  CAS  PubMed  Google Scholar 

Desikan KR, Tricot G, Munshi NC, Anaissie E, Spoon D, Fassas A, et al. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol. 2001;112:242–7.

Article  CAS  PubMed  Google Scholar 

Klaus J, Herrmann D, Breitkreutz I, Hegenbart U, Mazitschek U, Egerer G, et al. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol. 2007;78:21–8.

Article  PubMed  Google Scholar 

Shah N, Shi Q, Williams LA, Mendoza TR, Wang XS, Reuben JM, et al. Higher stem cell dose infusion after intensive chemotherapy does not improve symptom burden in older patients with multiple myeloma and amyloidosis. Biol Blood Marrow Transpl. 2016;22:226–31.

Article  Google Scholar 

Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, Guarini A, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transpl. 2006;37:719–24.

Article  CAS  Google Scholar 

Bolwell BJ, Pohlman B, Rybicki L, Sobecks R, Dean R, Curtis J, et al. Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transpl. 2007;40:437–41.

Article  CAS  Google Scholar 

Yoon DH, Sohn BS, Jang G, Kim EK, Kang BW, Kim C, et al. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin’s lymphoma. Transfusion. 2009;49:1890–900.

Article  CAS  PubMed  Google Scholar 

Blystad AK, Delabie J, Kvaløy S, Holte H, Vålerhaugen H, Ikonomou I, et al. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol. 2004;125:605–12.

Article  CAS  PubMed  Google Scholar 

Aladağ KarakulakE, Demiroğlu H, Büyükaşik Y, Turgut M, Aksu S, Sayinalp N, et al. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation. Turk J Med Sci. 2020;50:1851–6.

Article  Google Scholar 

Partanen A, Turunen A, Silvennoinen R, Valtola J, Pyörälä M, Siitonen T, et al. Impact of the number of cryopreserved CD34(+) cells in the infused blood grafts on hematologic recovery and survival in myeloma patients after autologous stem cell transplantation: experience from the GOA study. J Clin Apher. 2023;38:33–44.

Article  PubMed  Google Scholar 

Lebel E, Lajkosz K, Masih-Khan E, Reece D, Trudel S, Tiedemann R, et al. The impact of CD34(+) cell collection yields for autologous transplant on survival outcomes in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23:850–6.

Article  CAS  PubMed  Google Scholar 

Mohan M, Szabo A, Patwari A, Esselmann J, Patel T, Bachu R, et al. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone Marrow Transplant. 2024;59:647–652.

Davis JA, Sborov DW, Wesson W, Julian K, Abdallah AO, McGuirk JP, et al. Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA directed CAR T-cell therapy. Transpl Cell Ther. 2023;29:567–71.

Article  CAS  Google Scholar 

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e46.

Article  PubMed  Google Scholar 

Budczies J, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE. 2012;7:e51862.

Article  CAS  PubMed  Google Scholar 

Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39:33–8.

Article  Google Scholar 

Ho DE, Imai K, King G, Stuart EA. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Political Anal. 2007;15:199–236.

Article  Google Scholar 

Jantunen E, Turunen A, Varmavuo V, Partanen A. Impact of plerixafor use in the mobilization of blood grafts for autologous hematopoietic cell transplantation. Transfusion. 2024;64:742–50.

Article  CAS  PubMed  Google Scholar 

Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86:3961–9.

Article  CAS  PubMed  Google Scholar 

Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995;13:2547–55.

Article  CAS  PubMed  Google Scholar 

Raschle J, Ratschiller D, Mans S, Mueller BU, Pabst T. High levels of circulating CD34+ cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma. Br J Cancer. 2011;105:970–4.

Article  CAS  PubMed  Google Scholar 

Brioli A, Perrone G, Patriarca F, Pezzi A, Nobile F, Ballerini F, et al. Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. Bone Marrow Transpl. 2015;50:673–8.

Article  CAS  Google Scholar 

Kakihana K, Ohashi K, Akiyama H, Sakamaki H. Correlation between survival and number of mobilized CD34+ cells in patients with multiple myeloma or Waldenström macroglobulinemia. Pathol Oncol Res. 2010;16:583–7.

Article  PubMed  Google Scholar 

Vogel W, Kopp HG, Kanz L, Einsele H. Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J Cancer Res Clin Oncol. 2005;131:214–8.

Article  PubMed  Google Scholar 

Kopp HG, Yildirim S, Weisel KC, Kanz L, Vogel W. Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma. J Cancer Res Clin Oncol. 2009;135:637–42.

Article  CAS  PubMed  Google Scholar 

Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, et al. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J. 2023;13:68.

Article  PubMed  Google Scholar 

Lee SE, Lim JY, Kim TW, Ryu DB, Park SS, Jeon YW, et al. Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation. J Immunother Cancer. 2019;7:35.

Article  PubMed  Google Scholar 

Lim JY, Kim TW, Ryu DB, Park SS, Lee SE, Kim BS, et al. Myeloma-secreted galectin-1 potently interacts with CD304 on monocytic myeloid-derived suppressor cells. Cancer Immunol Res. 2021;9:503–13.

Article  CAS  PubMed  Google Scholar 

Tan CR, Derkach A, Nemirovsky D, Ciardiello A, Diamond B, Hultcrantz M, et al. Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma. Blood Cancer J. 2023;13:112.

Article  PubMed  Google Scholar 

Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390:301–13.

Article  CAS  PubMed  Google Scholar 

Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136:936–45.

Article  CAS  PubMed  Google Scholar 

Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29–38.

Article  CAS  PubMed  Google Scholar 

Lemonakis K, Tatting L, Lisak M, Carlson

留言 (0)

沒有登入
gif